TABLE 5.
Harm and Suicide-Related Adverse Events
| Emerged During Stage 1 |
Emerged During Stage 2 |
|||||
|---|---|---|---|---|---|---|
| Before Week 4 Decision |
Before Week 8 Decision |
Week 4 IR Add FLX |
Week 4 IR Increase IPT-A |
Week 8 IR Add FLX |
Week 8 IR Increase IPT-A |
|
| Outcome | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) |
| Harm-related | 3 (7.5%) | 3 (7.5%) | 2 (5.0%) | 1 (2.5%) | 3 (7.5%) | 2 (5.0%) |
| Suicide-related | 2 (5.0%) | 3 (7.5%) | 2 (5.0%) | 1 (2.5%) | 1 (2.5%) | 0 |
| Suicide attempt | 1 (2.5%) | 2 (5.0%) | 0 | 1 (2.5%) | 0 | 0 |
Note: FLX = fluoxetine; IPT-A = interpersonal psychotherapy for depressed adolescents; IR = insufficient responder.